Search Results

There are 6089 results for: content related to: Impact of hemochromatosis gene mutations on cardiac status in doxorubicin-treated survivors of childhood high-risk leukemia

  1. You have free access to this content
    The catalytic topoisomerase II inhibitor dexrazoxane induces DNA breaks, ATF3 and the DNA damage response in cancer cells

    British Journal of Pharmacology

    Volume 172, Issue 9, May 2015, Pages: 2246–2257, Shiwei Deng, Tiandong Yan, Teodora Nikolova, Dominik Fuhrmann, Andrea Nemecek, Ute Gödtel-Armbrust, Bernd Kaina and Leszek Wojnowski

    Version of Record online : 27 FEB 2015, DOI: 10.1111/bph.13046

  2. Cardioprotective interventions for cancer patients receiving anthracyclines

    Intervention Review

    The Cochrane Library

    Elvira C van Dalen, Huib N Caron, Heather O Dickinson and Leontien CM Kremer

    Published Online : 15 JUN 2011, DOI: 10.1002/14651858.CD003917.pub4

  3. Dexrazoxane exposure and risk of secondary acute myeloid leukemia in pediatric oncology patients

    Pediatric Blood & Cancer

    Volume 62, Issue 4, April 2015, Pages: 704–709, Alix E. Seif, Dana M. Walker, Yimei Li, Yuan-Shung V. Huang, Marko Kavcic, Kari Torp, Rochelle Bagatell, Brian T. Fisher and Richard Aplenc

    Version of Record online : 26 MAR 2014, DOI: 10.1002/pbc.25043

  4. You have free access to this content
    Role of hypoxia-inducible factors in the dexrazoxane-mediated protection of cardiomyocytes from doxorubicin-induced toxicity

    British Journal of Pharmacology

    Volume 163, Issue 2, May 2011, Pages: 299–312, RD Spagnuolo, S Recalcati, L Tacchini and G Cairo

    Version of Record online : 18 APR 2011, DOI: 10.1111/j.1476-5381.2011.01208.x

  5. You have free access to this content
    Dexrazoxane does not affect treatment outcome in non-Hodgkin's lymphoma patients

    American Journal of Hematology

    Volume 87, Issue 8, August 2012, Pages: 830–832, Anat Rabinovich, Dana Weiss, Maya Weissman, Victor Novack and Itai Levi

    Version of Record online : 31 MAY 2012, DOI: 10.1002/ajh.23250

  6. Dexrazoxane use in pediatric patients with acute lymphoblastic or myeloid leukemia from 1999 and 2009: Analysis of a national cohort of patients in the pediatric health information systems database

    Pediatric Blood & Cancer

    Volume 60, Issue 4, April 2013, Pages: 616–620, Dana M. Walker, Brian T. Fisher, Alix E. Seif, Yuan-Shung V. Huang, Kari Torp, Yimei Li and Richard Aplenc

    Version of Record online : 21 AUG 2012, DOI: 10.1002/pbc.24270

  7. Topoisomerase 2β: A Promising Molecular Target for Primary Prevention of Anthracycline-Induced Cardiotoxicity

    Clinical Pharmacology & Therapeutics

    Volume 95, Issue 1, January 2014, Pages: 45–52, P Vejpongsa and ETH Yeh

    Version of Record online : 19 DEC 2013, DOI: 10.1038/clpt.2013.201

  8. An In Vitro Comparison of the Effects of the Iron-Chelating Agents, CP94 and Dexrazoxane, on Protoporphyrin IX Accumulation for Photodynamic Therapy and/or Fluorescence Guided Resection

    Photochemistry and Photobiology

    Volume 87, Issue 6, November/December 2011, Pages: 1419–1426, Emma Blake, James Allen and Alison Curnow

    Version of Record online : 16 SEP 2011, DOI: 10.1111/j.1751-1097.2011.00985.x

  9. You have free access to this content
    Dexrazoxane protects the heart from acute doxorubicin-induced QT prolongation: a key role for IKs

    British Journal of Pharmacology

    Volume 159, Issue 1, January 2010, Pages: 93–101, J Ducroq, H Moha ou Maati, S Guilbot, S Dilly, E Laemmel, C Pons-Himbert, JF Faivre, P Bois, O Stücker and M Le Grand

    Version of Record online : 24 AUG 2009, DOI: 10.1111/j.1476-5381.2009.00371.x

  10. Pharmacokinetics of Dexrazoxane in Subjects With Impaired Kidney Function

    The Journal of Clinical Pharmacology

    Volume 51, Issue 5, May 2011, Pages: 731–738, Dr Michael E. Brier, Ms Shari K. Gaylor, Dr J. Patrick McGovren, Dr Paul Glue, Dr Annie Fang and Dr George R. Aronoff

    Version of Record online : 8 MAR 2013, DOI: 10.1177/0091270010369675

  11. You have free access to this content
    Prevention of cardiotoxicity among survivors of childhood cancer

    British Journal of Clinical Pharmacology

    Accepted manuscript online: 4 SEP 2016, Kelley K. Hutchins, Hani Siddeek, Vivian I. Franco and Steven E. Lipshultz

    DOI: 10.1111/bcp.13120

  12. Stereoselective metabolism of dexrazoxane (ICRF-187) and levrazoxane (ICRF-186)

    Chirality

    Volume 11, Issue 4, 1999, Pages: 286–290, Brian B. Hasinoff and Ronald G. Aoyama

    Version of Record online : 29 MAR 1999, DOI: 10.1002/(SICI)1520-636X(1999)11:4<286::AID-CHIR5>3.0.CO;2-5

  13. Dexrazoxane for the prevention of cardiomyopathy in anthracycline treated pediatric cancer patients

    Pediatric Blood & Cancer

    Volume 44, Issue 7, 15 June 2005, Pages: 584–588, Barry Anderson

    Version of Record online : 7 FEB 2005, DOI: 10.1002/pbc.20358

  14. Safety of concurrent administration of dexrazoxane and doxorubicin in the canine cancer patient

    Veterinary and Comparative Oncology

    Volume 8, Issue 4, December 2010, Pages: 273–282, W. M. FitzPatrick, N. G. Dervisis and B. E. Kitchell

    Version of Record online : 10 NOV 2010, DOI: 10.1111/j.1476-5829.2010.00225.x

  15. Use of the cardioprotectants thymosin β4 and dexrazoxane during congenital heart surgery: proposal for a randomized, double-blind, clinical trial

    Annals of the New York Academy of Sciences

    Volume 1270, Issue 1, October 2012, Pages: 59–65, Daniel Stromberg, Tia Raymond, David Samuel, David Crockford, William Stigall, Steven Leonard, Eric Mendeloff and Andrew Gormley

    Version of Record online : 10 OCT 2012, DOI: 10.1111/j.1749-6632.2012.06710.x

  16. Impaired mitochondrial function is abrogated by dexrazoxane in doxorubicin-treated childhood acute lymphoblastic leukemia survivors

    Cancer

    Volume 122, Issue 6, March 15, 2016, Pages: 946–953, Steven E. Lipshultz, Lynn M. Anderson, Tracie L. Miller, Mariana Gerschenson, Kristen E. Stevenson, Donna S. Neuberg, Vivian I. Franco, Daniel E. LiButti, Lewis B. Silverman, Lynda M. Vrooman, Stephen E. Sallan and for the Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium

    Version of Record online : 13 JAN 2016, DOI: 10.1002/cncr.29872

  17. You have free access to this content
    Activity of Dexrazoxane and Amifostine Against Late Cardiotoxicity Induced by the Combination of Doxorubicin and Cyclophosphamide In Vivo

    Basic & Clinical Pharmacology & Toxicology

    Volume 113, Issue 4, October 2013, Pages: 228–238, Snezana K. Bjelogrlic, Silvana T. Lukic and Slavisa M. Djuricic

    Version of Record online : 15 JUN 2013, DOI: 10.1111/bcpt.12086

  18. DOSE-INDEPENDENT PHARMACOKINETICS OF THE CARDIOPROTECTIVE AGENT DEXRAZOXANE IN DOGS

    Biopharmaceutics & Drug Disposition

    Volume 17, Issue 6, August 1996, Pages: 541–550, John R. Baldwin, Richard C. Lewis, Barbara A. Phillips, Stephen K. Overmyer, Naomi Z. Hatfield and Prem K. Narang

    Version of Record online : 4 DEC 1998, DOI: 10.1002/(SICI)1099-081X(199608)17:6<541::AID-BDD975>3.0.CO;2-5

  19. Outstanding neuroprotective efficacy of dexrazoxane in mice subjected to sequential common carotid artery sectioning

    Drug Development Research

    Volume 60, Issue 4, December 2003, Pages: 294–302, Rodolfo Rodriguez, Jacinto Santiago-Mejia, Monica Fuentes-Vargas and Eduardo Ramirez San-Juan

    Version of Record online : 12 NOV 2003, DOI: 10.1002/ddr.10330

  20. You have free access to this content
    Cardiac toxicity in cancer survivors

    Cancer

    Volume 119, Issue S11, 1 June 2013, Pages: 2131–2142, Daniel J. Lenihan, Stefano Oliva, Eric J. Chow and Daniela Cardinale

    Version of Record online : 20 MAY 2013, DOI: 10.1002/cncr.28061